L A Pemberton1, B J Brew. 1. Centre for Immunology, St. Vincent's Hospital, Darlinghurst, NSW 2010, Australia. l.pemberton@cfi.unsw.edu.au
Abstract
BACKGROUND: The astrocyte is thought to be important in AIDS dementia complex (ADC) pathogenesis on the basis of ADC neuropathology and cell culture models putatively because HIV can infect astrocytes leading to a compromise of their physiological detoxifying and neuronal support functions. Confirmatory in vivo data are lacking. Currently, the only widely available marker of the astrocyte is the protein S-100beta. OBJECTIVE: The aims of this study were to determine whether cerebrospinal fluid (CSF) levels of S-100beta correlate with the presence, severity and rapidity of ADC progression. STUDY DESIGN: Fourty nine CSF samples from HIV-1 seropositive individuals with either no ADC (ADC stage 0) or varying degrees of ADC (ADC stages 1-3) were analysed in this study. An immunoradiometric assay was used to quantify levels of S-100beta in the CSF. All individuals in this study were receiving antiretroviral therapy. In addition, individuals with ADC were grouped as either rapid ADC progressors or slow ADC progressors depending on the period of time from ADC diagnosis to death. RESULTS: CSF S-100beta levels in individuals with either ADC stage 2 or 3 were significantly elevated compared to those with stage 0 or 1. Moreover, CSF S-100beta levels were significantly higher in individuals with rapid ADC progression compared with slow progressors. CONCLUSIONS: This study shows that CSF S-100beta levels predict those patients in whom ADC will progress rapidly.
BACKGROUND: The astrocyte is thought to be important in AIDS dementia complex (ADC) pathogenesis on the basis of ADC neuropathology and cell culture models putatively because HIV can infect astrocytes leading to a compromise of their physiological detoxifying and neuronal support functions. Confirmatory in vivo data are lacking. Currently, the only widely available marker of the astrocyte is the protein S-100beta. OBJECTIVE: The aims of this study were to determine whether cerebrospinal fluid (CSF) levels of S-100beta correlate with the presence, severity and rapidity of ADC progression. STUDY DESIGN: Fourty nine CSF samples from HIV-1 seropositive individuals with either no ADC (ADC stage 0) or varying degrees of ADC (ADC stages 1-3) were analysed in this study. An immunoradiometric assay was used to quantify levels of S-100beta in the CSF. All individuals in this study were receiving antiretroviral therapy. In addition, individuals with ADC were grouped as either rapid ADC progressors or slow ADC progressors depending on the period of time from ADC diagnosis to death. RESULTS: CSF S-100beta levels in individuals with either ADC stage 2 or 3 were significantly elevated compared to those with stage 0 or 1. Moreover, CSF S-100beta levels were significantly higher in individuals with rapid ADC progression compared with slow progressors. CONCLUSIONS: This study shows that CSF S-100beta levels predict those patients in whom ADC will progress rapidly.
Authors: Andrew J Levine; Susan Service; Eric N Miller; Sandra M Reynolds; Elyse J Singer; Paul Shapshak; Eileen M Martin; Ned Sacktor; James T Becker; Lisa P Jacobson; Paul Thompson; Nelson Freimer Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2012-05-24 Impact factor: 3.568
Authors: Steven Paul Woods; Jennifer E Iudicello; Matthew S Dawson; Erica Weber; Igor Grant; Scott L Letendre Journal: J Clin Exp Neuropsychol Date: 2009-10-19 Impact factor: 2.475
Authors: Alex K Bryant; David J Moore; Tricia H Burdo; Jessica R Lakritz; Ben Gouaux; Virawudh Soontornniyomkij; Cristian L Achim; Eliezer Masliah; Igor Grant; Andrew J Levine; Ronald J Ellis Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: T J Barber; A Imaz; M Boffito; J Niubó; A Pozniak; R Fortuny; J Alonso; N Davies; S Mandalia; D Podzamczer; B Gazzard Journal: J Neurovirol Date: 2017-12-26 Impact factor: 2.643
Authors: Deanna Saylor; Alex M Dickens; Ned Sacktor; Norman Haughey; Barbara Slusher; Mikhail Pletnikov; Joseph L Mankowski; Amanda Brown; David J Volsky; Justin C McArthur Journal: Nat Rev Neurol Date: 2016-03-11 Impact factor: 42.937
Authors: N A Renner; R K Redmann; T Moroney-Rasmussen; H A Sansing; P P Aye; P J Didier; A A Lackner; A G Maclean Journal: Neuropathol Appl Neurobiol Date: 2012-04 Impact factor: 8.090
Authors: A Calcagno; A Romito; C Atzori; V Ghisetti; C Cardellino; S Audagnotto; E Scarvaglieri; F Lipani; D Imperiale; G Di Perri; S Bonora Journal: J Neuroimmune Pharmacol Date: 2016-11-08 Impact factor: 4.147